A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

As of January 1, 2025, about one out of every 18 Americans -- that's around 19 million folks -- was a cancer survivor. If you are diagnosed, one way to make sure that you have increased longevity is ...

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, you may be faced with multiple treatment options and asked to make a ...

Add Yahoo as a preferred source to see more of our stories on Google. Former President Joe Biden has completed a course of radiation therapy after being diagnosed in May with an "aggressive form" of ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...